Leo Shrimpton

Associate

Leo is an associate in the corporate team in Oxford. His work is primarily focused on the technology and life sciences sectors.

He has acted on university spin-outs, venture capital funding transactions, mergers and acquisitions and exits (often with an international element), the use of employee incentives such as enterprise management incentives, corporate restructuring and group reorganisations, shareholder and board advisory matters, general corporate governance, and other corporate law matters. Leo’s clients range from start-ups and owner-managed companies to large corporations. He has a pragmatic and commercial approach to advising on transactions, which is informed by his previous experience of working in-house.

I am a corporate lawyer with a particular interest in innovative life sciences and technology companies, and the entrepreneurs who run them. I enjoy getting to know my clients and their businesses, and developing a strong working relationship that allows me to really understand their unique challenges, and help them achieve their aims.

Leo Shrimpton, Associate

Leo studied law as a post-graduate at the University of Bristol. He then worked at a start-up, following which he trained and qualified at a major national law firm in 2020. After qualification, he spent a year working as an in-house solicitor at the family office of a high-net-worth individual, gaining experience of a wide variety of legal work and transactions. He joined Penningtons Manches Cooper in 2021.

Recent work highlights

Spin-out seed funding

Acting for Oxford University spin-out Ascension Earth Resources Ltd on its seed funding round led by Oxford Science Enterprises Ltd.

Specialist acquisition

Acting for Cibus Fund II, a specialist sustainable food and agriculture fund, on its acquisition of Alba Trees Plc.

Series B funding

Acting for moa Technology, an Oxford crop protection discovery company, on its £35 million series B funding round.

Private equity acquisition

Acting for the shareholders of Delta Hat Limited, a leading provider of analysis and health economic modelling to the life sciences and healthcare sectors, on its acquisition by Petauri, a New York-based private equity firm.

Series A funding

Acting for ToffeeX Limited, a developer of physics-driven generative design software, on its £5 million series A funding round.

International funding

Acting for Imperial College spin-out SPARTA Biodiscovery on its partnership and up to £3.5 million funding from international life sciences group, Sartorius.

Oxford acquisition

Acting for the shareholders of OXLiD, an Oxford-based lithium-sulfur battery technology developer, on its acquisition by AIM-listed Anglo-Australian battery innovator, Gelion.

Oxford acquisition

Acting for the shareholders of OXLiD, an Oxford-based lithium-sulfur battery technology developer, on its acquisition by AIM-listed Anglo-Australian battery innovator, Gelion.